Hyloris Pharmaceuticals SA (EBR:HYL)
Belgium
· Delayed Price · Currency is EUR 5.34
-0.06 (-1.11%)
Apr 28, 2026, 5:17 PM CET
Hyloris Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 7.21 | 8.46 | 2.09 | 0.9 | 3.1 | Upgrade
|
| Other Revenue | 1.63 | 1.3 | 1.67 | 1.49 | - | Upgrade
|
| Revenue | 8.83 | 9.76 | 3.76 | 2.39 | 3.1 | Upgrade
|
| Revenue Growth (YoY) | -9.50% | 159.64% | 57.48% | -22.90% | 1669.14% | Upgrade
|
| Cost of Revenue | 0.38 | 0.23 | 0.09 | 0.09 | 0.11 | Upgrade
|
| Gross Profit | 8.45 | 9.53 | 3.67 | 2.29 | 2.99 | Upgrade
|
| Selling, General & Admin | 4.88 | 5.63 | 5.55 | 3.52 | 2.9 | Upgrade
|
| Research & Development | 11.28 | 10.27 | 14.42 | 10.27 | 5.03 | Upgrade
|
| Other Operating Expenses | - | 0.01 | -0.46 | 0.01 | 5.38 | Upgrade
|
| Operating Expenses | 16.16 | 15.9 | 19.51 | 13.8 | 13.31 | Upgrade
|
| Operating Income | -7.71 | -6.37 | -15.85 | -11.51 | -10.33 | Upgrade
|
| Interest Expense | -0.74 | -0.08 | -0.05 | -0.22 | -0.56 | Upgrade
|
| Interest & Investment Income | 0.84 | 0.9 | 0.87 | 0.07 | 0.03 | Upgrade
|
| Earnings From Equity Investments | -0.07 | -0.08 | -0.15 | -0.13 | -0.19 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.26 | 0.02 | 0.35 | -0.19 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0.3 | -0.22 | -0.23 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | -7.68 | -5.66 | -15.38 | -11.68 | -11.26 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.97 | -0.97 | - | - | - | Upgrade
|
| Asset Writedown | - | - | - | - | -0.02 | Upgrade
|
| Legal Settlements | - | 0.29 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -0.23 | - | Upgrade
|
| Pretax Income | -6.71 | -6.34 | -15.38 | -11.9 | -11.28 | Upgrade
|
| Income Tax Expense | -0.37 | - | - | 0 | 0.3 | Upgrade
|
| Earnings From Continuing Operations | -6.33 | -6.34 | -15.38 | -11.91 | -11.58 | Upgrade
|
| Net Income | -6.33 | -6.34 | -15.38 | -11.91 | -11.58 | Upgrade
|
| Net Income to Common | -6.33 | -6.34 | -15.38 | -11.91 | -11.58 | Upgrade
|
| Shares Outstanding (Basic) | 28 | 28 | 28 | 27 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 28 | 28 | 27 | 26 | Upgrade
|
| Shares Change (YoY) | -1.65% | - | 2.95% | 5.29% | 18.40% | Upgrade
|
| EPS (Basic) | -0.23 | -0.23 | -0.55 | -0.44 | -0.45 | Upgrade
|
| EPS (Diluted) | -0.23 | -0.23 | -0.55 | -0.44 | -0.45 | Upgrade
|
| Free Cash Flow | -7 | -6.93 | -13.11 | -13.12 | -11.36 | Upgrade
|
| Free Cash Flow Per Share | -0.25 | -0.25 | -0.47 | -0.48 | -0.44 | Upgrade
|
| Gross Margin | 95.71% | 97.67% | 97.53% | 96.06% | 96.54% | Upgrade
|
| Operating Margin | -87.28% | -65.26% | -421.55% | -482.11% | -333.50% | Upgrade
|
| Profit Margin | -71.71% | -64.98% | -409.15% | -498.78% | -374.00% | Upgrade
|
| Free Cash Flow Margin | -79.23% | -71.03% | -348.66% | -549.69% | -366.83% | Upgrade
|
| EBITDA | -6.79 | -6.22 | -15.67 | -11.43 | -10.27 | Upgrade
|
| EBITDA Margin | -76.87% | -63.70% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.92 | 0.15 | 0.18 | 0.08 | 0.05 | Upgrade
|
| EBIT | -7.71 | -6.37 | -15.85 | -11.51 | -10.33 | Upgrade
|
| EBIT Margin | -87.28% | -65.26% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.